Synlife is pioneering the development of Synthetic Cells, which are engineered liposomes designed to replicate key functions of living cells, particularly metabolism. These Synthetic Cells are composed of complex systems of macromolecules, including highly active enzymes that form metabolic pathways. By deploying these cells as therapeutics, Synlife aims to enhance metabolic processes in targeted areas of the body, potentially addressing various medical conditions more effectively than current treatments.

The company has developed multiple formulations of Synthetic Cells for specific medical applications. Their lead product, SOBER, is focused on treating alcohol poisoning by facilitating the rapid removal of ethanol from the bloodstream, thereby reducing recovery time and improving patient outcomes. Additionally, Synlife is working on a combination therapy that utilizes Synthetic Cells to deliver chemotherapeutic agents directly to solid tumors, enhancing the efficacy of the treatment by converting drug precursors into their active forms at the tumor site. This innovative approach aims to improve the potency of cancer therapies while minimizing systemic side effects.

United States

Co-founded by MIT scientists in 2017 and headquartered in Cambridge, MA, Synlife's team is innovating new therapeutic and diagnostic platforms through bottom-up engineering of synthetic cells.

Synlife

Company Details